, lymph node involvement was the sole predictor for liver metastases. 14 Epidemiology of Ampullary Cancer Ampullary cancer accounts for only 0.2% of gastrointestinal cancers, but incidence has been increasing since 1970 at a rate of 0.5% to 0.9% per
Search Results
Molecular Targets and Therapies for Ampullary Cancer
Monica Arun Patel, Jeremy D. Kratz, Alexander S. Carlson, Ysaith Orellana Ascencio, Broc S. Kelley, and Noelle K. LoConte
Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer
Darren Sigal, Marie Tartar, Marin Xavier, Fei Bao, Patrick Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval, and Pratik Multani
burden, with reduced but persistent activity in the pelvic masses ( Figure 3B ). Although the bulkiest disease sites in the pelvis and skeleton showed clear improvement, some liver metastases responded whereas others had not. The patient had a stabilized
Intermittent Versus Continuous Androgen Deprivation Therapy
Celestia S. Higano
castration-sensitive disease had a 3-year survival rate of 69.0% with the addition of docetaxel versus 52.5% with ADT alone, and those with liver metastases, 4 or more bone lesions, or both had a 3-year survival of 63.4% and 43.9%, respectively. 17 These
Kidney Cancer, Version 3.2015
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar
for 5 years. The panel recommends annual chest radiograph or chest CT for 5 years to assess for pulmonary metastases in patients who have biopsy-proven low-risk RCC, nondiagnostic biopsies, or no prior biopsy to assess for liver metastases. The panel
Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction
Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa
with severe liver dysfunction Background Colorectal cancer (CRC) is the third most common cancer worldwide. 1 The liver is the most frequent site of metastatic CRC (mCRC). Patients with liver metastases and liver injury usually show poor
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
recurrent disease in the postsurgical bed and multiple liver metastases. He began gemcitabine and nab-paclitaxel for metastatic PDAC, but after 54 weeks imaging revealed progression of hepatic metastases. Subsequently, he was treated with second
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen
similar to findings in patients treated with chemotherapy. 18 However, liver metastases, which are also common in mNSCLC, have been associated with poor prognostic significance in patients treated using both chemotherapy and ICIs. 4 , 9 Recently
Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population
Urshila Durani, Dennis Asante, Thorvardur Halfdanarson, Herbert C. Heien, Lindsey Sangaralingham, Carrie A. Thompson, Prema Peethambaram, Fernando J. Quevedo, and Ronald S. Go
22. Kong G , Jackson C , Koh DM , . The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI . Eur J Nucl Med Mol Imaging 2008 ; 35 : 1323 – 1329 . 10.1007/s00259-008-0743-z 23. Ramos E , Martínez L
Clinical Impact of Local Progression in Pancreatic Cancer
Nicholas Cardillo, Daniel M. Seible, Katherine E. Fero, Andrew R. Bruggeman, Reith R. Sarkar, Alexa Azuara, Daniel R. Simpson, and James D. Murphy
Nakahashi et al, 7 which examined 89 patients with liver metastases and found that only a small fraction experienced hepatic failure as a result of metastatic involvement. Managing distant spread remains an important clinical goal in pancreatic cancer
Hormone Receptor–Positive Breast Cancer Sensitive to Pembrolizumab: Evidence of the Pathogenicity of the MLH1 Variant 1835del3
Henry G. Kaplan, Jeffrey R. Whiteaker, Brianna Nelson, Richard G. Ivey, Travis D. Lorentzen, Uliana Voytovich, Lei Zhao, David J. Corwin, Robert Resta, and Amanda G. Paulovich
changed to fulvestrant, tamoxifen, leuprolide, and denosumab. One year later her disease progressed again, and she received everolimus, fulvestrant, exemestane, and leuprolide. In 2014, she developed biopsy-proven liver metastases, with ER and PR
